Scarica l'app Stockscreener
8.75
4.04%
0.34
Dopo l'orario di chiusura:
9.09
0.34
+3.89%
Regenxbio Inc Borsa (RGNX) Ultime notizie
What is REGENXBIO Inc. company’s growth strategyChart Pattern Report Backed By Experts - jammulinksnews.com
REGENXBIO Inc. Reaches Critical Trendline SupportLow Capital High Return Stock Plans Reviewed - metal.it
REGENXBIO Inc. Inches Above Key Support — Safe to HoldTarget Return Focused Trade Insights Shared - metal.it
How many analysts rate REGENXBIO Inc. as a “Buy”AI Powered Tips For 2025 - jammulinksnews.com
Duchenne Muscular Dystrophy Market to Witness Significant Expansion During the Forecast Period (2025–2034) Amidst Advances in Gene Therapy and Novel Drug Approvals | DelveInsight - GlobeNewswire Inc.
What are the latest earnings results for REGENXBIO Inc.Get daily updates on promising stocks - jammulinksnews.com
What is the dividend policy of REGENXBIO Inc. stockRobust investment performance - jammulinksnews.com
What catalysts could drive REGENXBIO Inc. stock higher in 2025Maximize your portfolio’s earning power - jammulinksnews.com
What makes REGENXBIO Inc. stock price move sharplyBuild a portfolio that stands the test of time - jammulinksnews.com
What drives REGENXBIO Inc. stock priceJaw-dropping returns - PrintWeekIndia
What institutions are buying REGENXBIO Inc. stock nowTriple returns potential - jammulinksnews.com
REGENXBIO Inc. (RGNX): A Bull Case Theory - Insider Monkey
What analysts say about REGENXBIO Inc. stockStrong return on investment - Autocar Professional
The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place - insights.citeline.com
REGENXBIO Inc. Stock Analysis and ForecastExplosive trading opportunities - jammulinksnews.com
Is REGENXBIO Inc. a good long term investmentConsistently outstanding ROI - jammulinksnews.com
REGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the company - Yahoo Finance
(RGNX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO’s gene therapy with CT domain shows improved muscle function in study By Investing.com - Investing.com South Africa
REGENXBIO’s gene therapy with CT domain shows improved muscle function in study - Investing.com
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy - WV News
Diabetic Retinopathy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics - Barchart.com
RBC Capital Remains a Buy on RegenXBio (RGNX) - The Globe and Mail
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $21 - 富途牛牛
Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus
REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus
Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus
Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga
Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks
REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha
H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria
0.23%
0.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):